

Level 2, 66 Hunter Street  
Sydney NSW 2000  
Tel: (61-2) 9300 3344  
Fax: (61-2) 9221 6333  
E-mail: [pnightingale@biotron.com.au](mailto:pnightingale@biotron.com.au)  
Website: [www.biotron.com.au](http://www.biotron.com.au)

22 August 2016

The Manager Companies  
ASX Limited  
20 Bridge Street  
Sydney NSW 2000

(2 pages by email)

Dear Madam

### **ZIKA VIRUS PROGRAM UPDATE**

- **Additional Biotron compounds identified with activity against Zika virus**
- **Biotron executes agreement with NIAID for evaluation of Zika candidates**

**Sydney, Australia:** Biotron Limited (ASX: BIT) is pleased to advise that additional compounds in its proprietary compound library have shown activity against Zika virus.


As previously announced, Biotron has been screening its library of small molecule compounds against Zika virus. Previously, two compounds with anti-Zika activity were identified. Ongoing testing in cell culture assays has identified additional compounds that are able to inhibit Zika virus activity, several of which have greater potency against the virus than the first two compounds.

Recently, the Company executed an agreement under which the Company will utilise the non-clinical and pre-clinical services program offered by United State's National Institute of Allergy and Infectious Diseases (NIAID).

NIAID has identified Zika as a priority area for research funding, including creating treatments and broad-spectrum antiviral drugs that would be effective against the virus and similar diseases such as Dengue.

Biotron's CEO and Managing Director, Dr. Michelle Miller noted: "Biotron is delighted to have the opportunity to move ahead with the possible validation of our candidate molecules".

Yours sincerely



Peter J. Nightingale  
Company Secretary

pjn8595

## **About Biotron**

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on HIV-1 and Hepatitis C Virus (HCV). The Company has BIT225 in clinical development for both HIV-1 and HCV and also has several earlier stage preclinical and research programs for several other viral infections including Dengue.

### **Enquiries**

Dr Michelle Miller  
Managing Director  
Biotron Limited  
+61-(0)412313329

Rudi Michelson  
Monsoon Communications  
+61-3 9620 3333